Remove 2024 Remove Generic Medicine Remove Pharmaceutical Companies
article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. by the end of 2023 and may continue to rise in 2024 to 5%. Companies relying on angel investors and venture capitalists will be most affected by an economic downturn.

article thumbnail

STAT+: Pharmalittle: We’re reading about Lilly strategy against compounders, Bristol’s antipsychotic, and more

STAT

… Four months ago, a small pharmaceuticals company bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150% , STAT says. European pharmaceutical bosses have called on the European Union to increase drug prices toward the much higher levels paid by the U.S.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CHMP meeting highlights: February 2024

European Pharmaceutical Review

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.

article thumbnail

Farxiga generic availability, cost, and dosage

The Checkup by Singlecare

While brand-name drugs like Farxiga can be costly, people often want to know: When will a cost-saving generic be available? Is there a generic for Farxiga ? The pharmaceutical company Prasco currently markets a generic version of Farxiga.

Dosage 52
article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

More specifically, the Indian Pharmaceutical Alliance, an organisation representing the country’s largest pharmaceutical companies, has urged the government to reduce import tariffs from the current 10% to zero for pharmaceutical imports from the US.